Geneos Wealth Management’s CME Group CME Stock Holding History

Geneos Wealth Management’s Portfolio CME Stock Details CME Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.1M	Sell	3,735 -249	-6%	-$74K	0.03%	485
2025 Q4	$1.09M	Buy	3,984 +22	+0.6%	+$5.98K	0.03%	483
2025 Q3	$1.07M	Sell	3,962 -2,785	-41%	-$758K	0.03%	470
2025 Q2	$1.86M	Sell	6,747 -243	-3%	-$66.1K	0.05%	383
2025 Q1	$3.31M	Buy	6,990 +3,400	+95%	+$839K	0.05%	367
2024 Q4	$834K	Buy	3,590 +67	+2%	+$15.4K	0.03%	458
2024 Q3	$777K	Buy	3,523 +2,680	+318%	+$555K	0.03%	456
2024 Q2	$166K	Buy	843 +74	+10%	+$15.3K	0.01%	746
2024 Q1	$165K	Buy	769 +28	+4%	+$5.88K	0.01%	740
2023 Q4	$156K	Sell	741 -287	-28%	-$61.2K	0.01%	732
2023 Q3	$206K	Buy	1,028 +168	+20%	+$33.4K	0.01%	680
2023 Q2	$159K	Sell	860 -185	-18%	-$34.2K	0.01%	735
2023 Q1	$200K	Buy	1,045 +584	+127%	+$106K	0.01%	651
2022 Q4	$77.5K	Buy	461 +30	+7%	+$5.21K	﹤0.01%	902
2022 Q3	$76K	Sell	431 -465	-52%	-$91.9K	0.01%	880
2022 Q2	$183K	Hold	896	–	–	0.01%	776
2022 Q1	$213K	Sell	896 -100	-10%	-$23.5K	0.01%	778
2021 Q4	$227K	Buy	996 +423	+74%	+$93.1K	0.01%	809
2021 Q3	$112K	Hold	573	–	–	﹤0.01%	1122
2021 Q2	$122K	Sell	573 -614	-52%	-$130K	﹤0.01%	1081
2021 Q1	$239K	Hold	1,187	–	–	0.01%	895
2020 Q4	$190K	Buy	1,187 +359	+43%	+$61.1K	0.01%	843
2020 Q3	$138K	Sell	828 -4	-0.5%	-$674	0.01%	813
2020 Q2	$135K	Sell	832 -330	-28%	-$59.2K	0.01%	790
2020 Q1	$199K	Sell	1,162 -414	-26%	-$82.4K	0.01%	611
2019 Q4	$319K	Buy	1,576 +75	+5%	+$15.4K	0.02%	544
2019 Q3	$321K	Buy	1,501 +301	+25%	+$62.9K	0.02%	508
2019 Q2	$233K	Sell	1,200 -4	-0.3%	-$737	0.01%	614
2019 Q1	$198K	Sell	1,204 -101	-8%	-$17.9K	0.01%	641
2018 Q4	$242K	Buy	1,305 +43	+3%	+$7.94K	0.02%	550
2018 Q3	$214K	Buy	1,262 +191	+18%	+$32.2K	0.01%	615
2018 Q2	$175K	Sell	1,071 -65	-6%	-$10.6K	0.01%	600
2018 Q1	$183K	Buy	1,136 +18	+2%	+$2.87K	0.02%	565
2017 Q4	$163K	Buy	1,118 +382	+52%	+$54.4K	0.01%	592
2017 Q3	$99K	Hold	736	–	–	0.01%	702
2017 Q2	$92K	Sell	736 -26	-3%	-$3.11K	0.01%	705
2017 Q1	$90K	Sell	762 -4	-0.5%	-$481	0.01%	688
2016 Q4	$88K	Hold	766	–	–	0.01%	647
2016 Q3	$80K	Buy	766 +30	+4%	+$3.13K	0.01%	652
2016 Q2	$70K	Hold	736	–	–	0.01%	690
2016 Q1	$71K	Buy	+736	New	+$67K	0.01%	681

Other funds holding CME

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Geneos Wealth Management's CME Position: Q1 2026 in Review

Geneos Wealth Management reduced its CME Group (CME) stake by 6.3% in Q1 2026, selling an estimated $74K and leaving 3,735 shares worth $1.1M. The position accounts for 0.03% of the portfolio, ranked #485.

Geneos Wealth Management first reported a position in CME in Q1 2016 and has held it in 41 quarters since. The position peaked at $3.31M in Q1 2025. 1,790 funds tracked by Wall St. Rank hold CME as of Q1 2026.

Geneos Wealth Management held 3,735 shares of CME Group worth $1.1M as of Q1 2026.
Geneos Wealth Management sold 249 CME Group shares in Q1 2026, an estimated $74K.
CME Group made up 0.03% of Geneos Wealth Management's portfolio in Q1 2026, its #485 holding.
Geneos Wealth Management first reported a position in CME Group in Q1 2016 and has held it in 41 quarters since.
Geneos Wealth Management's CME Group position peaked at $3.31M in Q1 2025.
1,790 funds tracked by Wall St. Rank held CME Group as of Q1 2026.

Based on Geneos Wealth Management's 13F filing for Q1 2026, filed 5 May 2026.